FDA Exempts COVID-19 Prescription Drugs From DSCSA Tracing Requirements
Executive Summary
Prescription drugs that are deemed necessary for treating patients in public health emergencies such as COVID-19 would not have to comply with DSCSA tracing requirements, says the FDA. Such drugs would not need to have product identifiers and saleable returns would not have to be verified.
You may also be interested in...
US FDA Still “Actively” Drafting Proposed Licensing Rule For Wholesalers and 3PLs
Pharmaceutical manufacturers should have already begun serializing products and verifying saleable returns to comply with DSCSA, says FDA official who also asserted that licensing standards for wholesale distributors and third-party logistics providers will be forthcoming. This rule is already six years overdue under a DSCSA mandated timeline.
After Remdesivir's Emergency Use Authorization, US Gov't Must Now Decide How To Distribute Limited Supply
Gilead's antiviral remdesivir will go to hospitalized severe COVID-19 patients per FDA's EUA. Some cities could receive the medicine with days, but it is not clear how the government will dole out the limited supplies. FDA said it had access to non-public data from a key NIH trial during its EUA review.
COVID-19 Could Offer Some DSCSA Enforcement Relief For Manufacturers
As the US FDA focuses on COVID-19 pandemic-related activities, the time may be right to ask for an extension in complying with the DSCSA’s saleable returns verification deadline.